Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its participation in the 2020 ASDS Virtual Annual Meeting, where it will present data on its genomic tests for skin cancer. Notable presentations include:
- Clinical validation of a 40-gene test for cSCC by Sherrif Ibrahim, M.D., Ph.D., on October 9, 2020.
- Prognostic model combining a 31-gene test with sentinel lymph node biopsy by Aaron Farberg, M.D., also on October 9, 2020.
The presentations will be available for registrants for 30 days post-meeting.